Table 2.

Univariable and multivariable analysis.

Univariable
Variable		RFS		OS
		HR (95% CI)	p	HR (95% CI)	p
Age (continuous)		1.01 (1.00–1.03)	0.125	1.02 (1.00–1.03)	0.140
Race	White	1		1
	Non-white	1.08 (0.67–1.72)	0.754	0.94 (0.53–1.66)	0.821
Germline BRCA1/2 mutation	Yes	1		1
	No	1.34 (0.69–2.61)	0.383	1.67 (0.72–3.88)	0.232
ER/PR expression group	TNBC	1		1
	Low-ER	1.11 (0.62–1.99)	0.729	1.12 (0.60–2.30)	0.633
Grade	1–2	1		1
	3	1.15 (0.66–1.99)	0.630	0.95 (0.52–1.73)	0.865
T stage	T1/2	1		1
	T3/4	3.42 (2.19–5.34)	<0.001	4.40 (2.69–7.19)	<0.001
Nodal status	Negative	1		1
	Positive	2.65 (1.77–3.96)	<0.001	3.28 (2.04–5.26)	<0.001
Surgery type	Lumpectomy	1		1
	Mastectomy	1.53 (0.99–2.37)	0.053	1.56 (0.94–2.59)	0.082
Adjuvant radiation therapy	No	1		1
	Yes	1.77 (1.13–2.77)	0.011	1.85 (1.10–3.11)	0.018
Chemotherapy setting	Neoadjuvant	1		1
	Adjuvant	0.81 (0.51–1.27)	0.354	0.85 (0.51–1.43)	0.547
Adjuvant endocrine therapy	No	1		1
	Yes	1.81 (0.79–4.13)	0.155	1.56 (0.57–4.28)	0.382

Multivariable
Variable		RFS		OS
		HR (95% CI)	p	HR (95% CI)	p
T stage	T1/2	1		1
	T3/4	2.36 (1.44–3.88)	0.001	3.19 (1.84–5.52)	<0.001
Nodal status	Negative	1		1
	Positive	1.79 (1.12–2.87)	0.015	2.25 (1.31–3.89)	0.004
Surgery type	Lumpectomy	1		1
	Mastectomy	1.39 (0.83–2.31)	0.210	1.16 (0.64–2.11)	0.615
Adjuvant radiation therapy	No	1		1
	Yes	1.66 (0.98–2.82)	0.059	1.57 (0.85–2.89)	0.146
Adjuvant endocrine therapy	No	1		1
	Yes	1.23 (0.48–3.17)	0.670	0.92 (0.29–2.89)	0.880
ER/PR expression group	TNBC	1		1
	Low-ER	1.23 (0.63–2.40)	0.540	1.44 (0.67–3.06)	0.350